Santen Pharmaceutical Company Insiders
| SNPHY Stock | USD 9.23 0.20 2.12% |
Santen Pharmaceutical employs about 4.3 K people. The company is managed by 38 executives with a total tenure of roughly 153 years, averaging almost 4.0 years of service per executive, having 113.55 employees per reported executive. Break down of Santen Pharmaceutical's management performance can provide insight into the company performance.
| Akira Kurokawa CEO CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee |
| Naveed Shams CEO Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary |
Santen |
Santen Pharmaceutical Management Team Effectiveness
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Santen Pharmaceutical Workforce Comparison
Santen Pharmaceutical Co is currently regarded as top stock in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is at this time estimated at about 131,672. Santen Pharmaceutical holds roughly 4,315 in number of employees claiming about 3% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of (0.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Santen Pharmaceutical Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Santen Pharmaceutical Price Series Summation is a cross summation of Santen Pharmaceutical price series and its benchmark/peer.
Santen Pharmaceutical Notable Stakeholders
A Santen Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Santen Pharmaceutical often face trade-offs trying to please all of them. Santen Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Santen Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Akira Kurokawa | CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee | Profile | |
| Naveed Shams | Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary | Profile | |
| Jyrki Liljeroos | Executive Officer and Presidentident of Subsidiary | Profile | |
| Shigeo Taniuchi | Executive Officer and Presidentident of Subsidiary | Profile | |
| Kazuo Koshiji | CFO, Head of Fin. Division and Sr. Corporate Officer | Profile | |
| Satoshi Suzuki | Executive Officer, Chief Director of Planning | Profile | |
| Kanoko Ohishi | Independent Director | Profile | |
| Kenji Morishima | Executive Officer, Chief Director of Human Resources & Organization Development and CSR | Profile | |
| Sadatoshi Furukado | Senior Managing Executive Officer, Director of Medical Business, Director | Profile | |
| Ken Araki | Executive Officer, Senior Director of Global Business Development | Profile | |
| Akihiro Tsujimura | Executive Officer, Director of Asia Business | Profile | |
| Takeshi Ito | Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | Profile | |
| Frank Binder | Executive Officer, Chief Director of Supply Chain | Profile | |
| Yutaro Shintaku | Independent Director | Profile | |
| Akihiro Okumura | Independent Director | Profile | |
| Yutaro Shinta | Independent Director | Profile | |
| Keizo Nakada | Executive Officer, Chief Director of Product Supply | Profile | |
| Akio Kimura | Executive Officer, Chief Director of Reliability Guarantee | Profile | |
| Miki Fujima | Executive Officer, Chief Director of Human Resources | Profile | |
| Atsutoshi Ohta | Executive Officer, Chief Director of Production & Logistics | Profile | |
| Hiroyuki Yamazaki | Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | Profile | |
| Takahiro Morita | Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit | Profile | |
| Takayuki Katayama | Independent Director | Profile | |
| Kunihito Minakawa | Independent Director | Profile | |
| Nikolas Tripodis | Chief Officer | Profile | |
| Noriaki Yamamoto | CIO, Head of Information Systems Division and Corporate Officer | Profile | |
| Hidetaka Mizutani | Manager of Finance & Accounting Group | Profile | |
| Nobuko Kato | Chief Officer | Profile | |
| Mika Masunari | G Officer | Profile | |
| Masamichi Sato | Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel. | Profile | |
| Kaori Itagaki | Gen Group | Profile | |
| Shinichi Teramachi | Head Officer | Profile | |
| Ippei Kurihara | Japan Department | Profile | |
| Shiro Hatagami | Manager of Finance & Accounting Group | Profile | |
| Ko Takahashi | Executive Officer | Profile | |
| Ye Liu | Executive Officer, General Manager of Subsidiary | Profile | |
| Luis Iglesias | Executive Officer | Profile | |
| Minori Hara | Chief Officer | Profile |
About Santen Pharmaceutical Management Performance
The success or failure of an entity such as Santen Pharmaceutical often depends on how effective the management is. Santen Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Santen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Santen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people.
The data published in Santen Pharmaceutical's official financial statements usually reflect Santen Pharmaceutical's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Santen Pharmaceutical. For example, before you start analyzing numbers published by Santen accountants, it's critical to develop an understanding of what Santen Pharmaceutical's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Santen Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Santen Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Santen Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Santen Pharmaceutical Co. Please utilize our Beneish M Score to check the likelihood of Santen Pharmaceutical's management manipulating its earnings.
Santen Pharmaceutical Workforce Analysis
Traditionally, organizations such as Santen Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Santen Pharmaceutical within its industry.Santen Pharmaceutical Manpower Efficiency
Return on Santen Pharmaceutical Manpower
| Revenue Per Employee | 61.7M | |
| Revenue Per Executive | 7B | |
| Net Income Per Employee | 6.3M | |
| Net Income Per Executive | 716.3M | |
| Working Capital Per Employee | 24.6M | |
| Working Capital Per Executive | 2.8B |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santen Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Santen Pharmaceutical information on this page should be used as a complementary analysis to other Santen Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |